Heritage Investors Management Corp Acquires Shares of 7,728 Exelixis, Inc. (NASDAQ:EXEL)

Heritage Investors Management Corp acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) in the third quarter, HoldingsChannel.com reports. The firm acquired 7,728 shares of the biotechnology company’s stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EXEL. V Square Quantitative Management LLC bought a new position in shares of Exelixis during the third quarter valued at $30,000. Park Place Capital Corp bought a new position in shares of Exelixis during the second quarter valued at $45,000. GAMMA Investing LLC lifted its holdings in shares of Exelixis by 107.9% during the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 1,041 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Exelixis by 537.2% during the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,746 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in shares of Exelixis during the third quarter valued at $74,000. 85.27% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Exelixis news, EVP Jeffrey Hessekiel sold 20,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.79, for a total transaction of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at approximately $16,256,081.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director George Poste sold 30,000 shares of Exelixis stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the transaction, the director now owns 169,020 shares in the company, valued at $5,746,680. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.79, for a total value of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 339,020 shares of company stock worth $9,737,866. Insiders own 2.85% of the company’s stock.

Exelixis Trading Up 1.4 %

Shares of EXEL opened at $34.77 on Wednesday. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $35.15. The stock has a market cap of $9.93 billion, a P/E ratio of 22.08, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51. The stock’s 50-day moving average price is $27.30 and its two-hundred day moving average price is $24.39.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. During the same quarter last year, the business earned $0.10 earnings per share. The company’s revenue was up 14.3% compared to the same quarter last year. As a group, equities analysts forecast that Exelixis, Inc. will post 1.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on EXEL shares. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. TD Cowen raised their target price on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Morgan Stanley raised their target price on Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, October 11th. Wells Fargo & Company raised their target price on Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Finally, Bank of America raised their target price on Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.